Skip to main content
Log in

Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy

  • Diagnostic Neuroradiology
  • Published:
Neuroradiology Aims and scope Submit manuscript

Abstract

Since antineoplastic activity varies, sensitive methods for individual assessment of efficacy are needed. We demonstrate the clinical value of MR spectroscopy in monitoring chemotherapy in a patient with recurrent glioma after stereotactic radiotherapy. Diagnostic imaging before and after chemotherapy included contrast–enhanced MRI, single–voxel proton MR spectroscopy (1H MRS), 1H MR spectroscopic imaging (1H SI), and fluorodeoxyglucose (FDG) positron-emission tomography (PET). A significant decrease in choline signal intensity was observed 2 months after chemotherapy indicating tumour chemosensitivity, in line with tumour shrinkage on MRI and decreased uptake of FDG. Assessment of early response by MRS may help to improve treatment protocols in other patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–h
Fig. 2a–h
Fig. 3

Similar content being viewed by others

References

  1. Kappelle AC, Prostma TJ, Taphoorn MJ, et al (2001) PCV chemotherapy for recurrent glioblastoma multiforme. J Clin Oncol 19: 509–518

    PubMed  Google Scholar 

  2. Langleben DD, Segall DM (2000) PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41: 1861–1867

    CAS  PubMed  Google Scholar 

  3. Nelson SJ (2001) Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med 46: 228–239

    Article  CAS  PubMed  Google Scholar 

  4. Preul MC, Caramanos Z, Collins DL, et al (1996) Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nature Medicine 2: 323–325

    CAS  PubMed  Google Scholar 

  5. Meyerand ME, Pipas JM, Mamourian A, Tosteson TD, Dunn, JF (1999) Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR 20: 117–123

    CAS  PubMed  Google Scholar 

  6. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G (2001) Evaluation of suspicious brain lesions after stereotactic radiotherapy of brain tumors using proton MR spectroscopy. AJNR 22: 1316–1324

    CAS  PubMed  Google Scholar 

  7. Chan YL, Yeung DK, Leung SF, Cao G (1999) Proton magnetic resonance spectroscopy of late delayed radiation–induced injury of the brain. J Magn Reson Imag 10: 130–137

    Article  CAS  Google Scholar 

  8. Preul MC, Caramanos Z, Villemure JG, et al (2000) Using proton magnetic resonance spectroscopy imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46: 306–318

    Article  CAS  PubMed  Google Scholar 

  9. Soher BJ, Young K, Govindaraju V, Maudsley AA (1998) Automated spectral analysis III: Application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Reson Med 40:822–831

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. P. Lichy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lichy, M.P., Bachert, P., Henze, M. et al. Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 46, 126–129 (2004). https://doi.org/10.1007/s00234-003-1116-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00234-003-1116-8

Keywords

Navigation